Preliminary data demonstrated that the Unyvero HPN panel was strongly concordant with bacterial culture for organism targets, confirming all pathogens reported by culture in 31 out of 35 patient samples.
Pediatric HIV infection and HIV exposure without infection both had an association with carriage prevalence and densities for Streptococcus pneumoniae and Pneumocystis jirovecii.
Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in combination with methotrexate (MTX) was shown to be successful and well-tolerated in patients with chronic inflammatory/autoimmune diseases.
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
A parsimonious score system that accurately identified elderly and non-elderly patients with pneumonia at highest risk for mortality in the intensive care unit has been developed.
Pfizer announced topline data from one of its phase 3 studies for 20vPnC for the prevention of invasive disease and pneumonia.
Anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy in addition to standard pneumonia therapy does not improve mortality.
The FDA has accepted for review a sNDA for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
The FDA has requested that all manufacturers of bacitracin for injection voluntarily withdraw their product from the market.
As of Jan. 2, 2020, 41 patients were admitted with laboratory-confirmed 2019 novel coronavirus (2019-nCoV), all of whom had pneumonia.
